Goodwin Biotechnology, Inc. Announces a Collaboration With Alethia BioTherapeutics, Inc.
6/2/2011 10:06:13 AM
More...
|
Alethia BioTherapeutics, Inc. Secures C$9.6 Million in Series A Financing to Fund Its Therapeutic Monoclonal Antibody Product Pipeline
9/7/2010 6:29:42 AM
More...
|
Alethia BioTherapeutics, Inc. Strengthens its Board of Directors
12/15/2009 10:09:03 AM
More...
|
Alethia BioTherapeutics, Inc. Announces in-Licensing of a Peptide for Imaging of Solid Tumors in vivo and Positive Pre-Clinical Results of AB-16B5 in Prostate and Breast Cancer
12/7/2009 10:52:33 AM
More...
|
Alethia BioTherapeutics, Inc. Exercises its Option to License Clusterin-Specific Antibodies for Cancer Therapeutics and Diagnostics
5/6/2009 7:20:03 AM
More...
|
Alethia BioTherapeutics, Inc. Closes $2.2 M Financing - Proceeds to Advance Pre-Clinical Development of Lead Drug Candidates
4/23/2009 11:57:03 AM
More...
|
BDC Venture Capital and GO Capital Invest in Alethia BioTherapeutics, Inc., a Montreal Biotechnology Firm
4/3/2008 9:51:23 AM
More...
|
Alethia BioTherapeutics, Inc. Announces in-Licensing of Family of Monoclonal Antibodies to Treat Metastatic Cancer
10/3/2007 8:32:15 AM
More...
|
Alethia BioTherapeutics, Inc. and Emerillon Therapeutics Inc. Announce Collaborative Agreement for Target Discovery in Bone-Related Diseases
5/1/2007 11:01:55 AM
More...
|
Alethia BioTherapeutics, Inc. Announces Collaborative Agreement With Biosite Incorporated (BSTE) for Antibody Development in Ovarian Cancer
3/12/2007 10:19:02 AM
More...
|
|